Boundless Bio

Boundless Bio uses its Spyglass platform to map ecDNA blueprints, identifying targets to develop tailored therapies for hard-to-treat cancers.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2024
Stage of Initial Investment
Series B
Initial Investment Year
2021